GERN
Geron Corporation
NASDAQ · Healthcare · Biotechnology · US
$1.57
+3.97%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
93.8x
EV/EBITDA
−19.9x
Market Cap
$1.01B
MomentumView details →
1D Return
+3.97%
YTD Return
+14.39%
RSI (14)
50.8
ValuationView details →
P/E (Fwd)
93.8x
EV/EBITDA
−19.9x
Market Cap
$1.01B
RSI (14)
50.8
MomentumView details →
1D Return
+3.97%
YTD Return
+14.39%
SummaryUpdated Jun 1, 2026
Geron Corporation (NASDAQ:GERN) is a late-stage clinical biopharmaceutical company founded in 1990 and headquartered in Foster City, California. The company went public in 1996 and has focused its efforts on developing therapeutics for blood cancers, specifically myeloid hematologic malignancies. After decades of research and development, Geron achieved a significant milestone in June 2024 with the FDA approval of its lead drug candidate, imetelstat, which is now marketed under the brand name <b>RYTELO</b>. The company has transitioned from a purely clinical-stage entity to a commercial organization with its first approved product generating revenue.
Similar companies
Latest newsMore news →
Geron Corporation reported second quarter 2026 financial results, with RYTELO net product revenue of $57.5 million, an 11% increase from the first quarter of 2026, and cash and marketable securities of $327 million at the end of the quarter.30d agoGeron Corporation appointed Chinmaya Rath as Chief Business Officer.53d ago